Eduardo M. M.
- Country
- Spain
- Department
- Neumología
Research Overview
- Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Trial of Lunsekimig in Adults with Inadequately Controlled Eosinophilic COPD
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Anti-TSLP Antibody GSK5784283 in Adults with Uncontrolled Asthma
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of WIN378 (Human IgG1 Monoclonal Antibody Against TSLP) in Adults with Moderate to Severe Asthma
Data & Insights
Has run more than one trial at 18 of 150 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in treating patients with uncontrolled asthma, with particular emphasis on innovative therapeutic approaches using targeted antibody treatments.
- Airway Inflammation Management
- Biomarker Assessment
- Respiratory Function Testing
Their research involves evaluating novel treatments targeting thymic stromal lymphopoietin (TSLP) pathways in respiratory conditions.
Diagnostic Innovation
The investigator utilizes advanced diagnostic techniques including fraction of exhaled nitric oxide (FeNO) measurements to assess airway inflammation and treatment response.
- Inflammatory Biomarker Analysis
- Respiratory Assessment Techniques
- Treatment Response Monitoring
Their work focuses on implementing precise diagnostic methods for respiratory disease management.
Therapeutic Development
The investigator explores novel biological therapies for respiratory conditions, particularly focusing on patients aged 18 to 75 years with difficult-to-treat asthma.
- Antibody-Based Treatments
- Dose Optimization Studies
- Adult Asthma Management
Their research contributes to advancing targeted therapeutic approaches in respiratory medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.